Weiss Ratings Reiterates Sell (E+) Rating for 111 (NASDAQ:YI)

111 (NASDAQ:YI)‘s stock had its “sell (e+)” rating restated by equities research analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

111 Stock Performance

Shares of YI stock opened at $7.40 on Wednesday. The stock’s fifty day moving average is $7.80 and its 200-day moving average is $7.56. The stock has a market capitalization of $63.97 million, a PE ratio of -1.85 and a beta of 0.47. 111 has a 52 week low of $4.15 and a 52 week high of $12.90.

111 (NASDAQ:YI) last announced its earnings results on Thursday, March 20th. The company reported ($0.04) EPS for the quarter. The firm had revenue of $527.14 million during the quarter.

Hedge Funds Weigh In On 111

Hedge funds have recently added to or reduced their stakes in the company. Deuterium Capital Management LLC bought a new position in 111 in the first quarter valued at about $81,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in 111 in the first quarter valued at about $92,000. JPMorgan Chase & Co. boosted its holdings in 111 by 43,619.9% in the fourth quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock valued at $191,000 after acquiring an additional 305,339 shares during the last quarter. Napean Trading & Investment Co Singapore PTE Ltd bought a new position in 111 in the fourth quarter valued at about $245,000. Finally, FIL Ltd bought a new position in 111 in the fourth quarter valued at about $450,000. Institutional investors own 21.32% of the company’s stock.

About 111

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.